AR007715A1 - Formulacion acuosa estable de un peptido, un metodo para preparar la misma y su uso para tratamiento - Google Patents

Formulacion acuosa estable de un peptido, un metodo para preparar la misma y su uso para tratamiento

Info

Publication number
AR007715A1
AR007715A1 ARP970102966A ARP970102966A AR007715A1 AR 007715 A1 AR007715 A1 AR 007715A1 AR P970102966 A ARP970102966 A AR P970102966A AR P970102966 A ARP970102966 A AR P970102966A AR 007715 A1 AR007715 A1 AR 007715A1
Authority
AR
Argentina
Prior art keywords
peptide
stable aqueous
preparing
treatment
aqueous formulation
Prior art date
Application number
ARP970102966A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR007715A1 publication Critical patent/AR007715A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a formulaciones líquidas acuosas estables de compuestos péptidos a altas concentraciones. Estas formulaciones estables comprenden por lo menosaproximadamente 10% de péptido en agua. Ellas pueden ser almacenadas a elevadastemperat uras por largos períodos de tiempo y son especialmente útilesen dispositivos de liberación implantables para largos téminos de liberación de droga. Formulación acuosa estable de un péptido, un método para preparar lamisma y su uso paratratamiento.
ARP970102966A 1996-07-03 1997-07-02 Formulacion acuosa estable de un peptido, un metodo para preparar la misma y su uso para tratamiento AR007715A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2119996P 1996-07-03 1996-07-03

Publications (1)

Publication Number Publication Date
AR007715A1 true AR007715A1 (es) 1999-11-10

Family

ID=21802912

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102966A AR007715A1 (es) 1996-07-03 1997-07-02 Formulacion acuosa estable de un peptido, un metodo para preparar la misma y su uso para tratamiento

Country Status (26)

Country Link
US (2) US5916582A (es)
EP (1) EP0909177B1 (es)
JP (2) JP2001504442A (es)
CN (1) CN1256146C (es)
AR (1) AR007715A1 (es)
AT (1) ATE259241T1 (es)
AU (1) AU3574897A (es)
BR (1) BR9710131A (es)
CA (1) CA2259505A1 (es)
CO (1) CO4890855A1 (es)
CZ (1) CZ298464B6 (es)
DE (1) DE69727572T2 (es)
ES (1) ES2213828T3 (es)
HU (1) HU225691B1 (es)
ID (1) ID19305A (es)
IL (1) IL127770A (es)
MY (1) MY125556A (es)
NO (1) NO323296B1 (es)
NZ (1) NZ333579A (es)
PL (1) PL189403B1 (es)
RO (1) RO120611B1 (es)
RU (1) RU2201248C2 (es)
SK (1) SK284283B6 (es)
TW (1) TW586932B (es)
WO (1) WO1998000157A1 (es)
ZA (1) ZA975943B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7193521B2 (en) 1998-10-29 2007-03-20 Medtronic Minimed, Inc. Method and apparatus for detecting errors, fluid pressure, and occlusions in an ambulatory infusion pump
CA2345439C (en) 1998-10-29 2005-08-09 Minimed, Inc. Compact pump drive system
US20020173748A1 (en) 1998-10-29 2002-11-21 Mcconnell Susan Reservoir connector
US6248093B1 (en) 1998-10-29 2001-06-19 Minimed Inc. Compact pump drive system
US6800071B1 (en) 1998-10-29 2004-10-05 Medtronic Minimed, Inc. Fluid reservoir piston
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7063684B2 (en) 1999-10-28 2006-06-20 Medtronic Minimed, Inc. Drive system seal
HRP20050371B1 (hr) * 2002-09-27 2014-09-26 Zentaris Gmbh Oblik za primjenu farmaceutiski djelatnih peptida s produljenim oslobađanjem djelatnog sastojka i postupak za njihovu proizvodnju
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
EP1838290A2 (en) * 2005-01-21 2007-10-03 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
US8137664B2 (en) * 2005-02-02 2012-03-20 Sdgi Holdings, Inc. Method and kit for repairing a defect in bone
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20080200383A1 (en) * 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
CN100336557C (zh) * 2005-05-11 2007-09-12 北京双鹭药业股份有限公司 一种生长抑素的水溶液制剂、其制备方法及应用
US20060293243A1 (en) * 2005-06-17 2006-12-28 Navneet Puri Stable, buffered, pharmaceutical compositions including motilin-like peptides
US20060287243A1 (en) * 2005-06-17 2006-12-21 Navneet Puri Stable pharmaceutical compositions including motilin-like peptides
ES2426445T3 (es) * 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
EP2190457A1 (en) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Use of a defensin peptide as a therapeutic agent
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009137080A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of gnrh related compounds and processes of preparation
MX385591B (es) 2008-08-15 2025-03-18 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
EP2246063A1 (en) 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. Sustained release formulations comprising GnRH analogues
WO2011017502A2 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
CN102869677B (zh) 2010-02-17 2015-07-08 硬木药品公司 胃肠病症的治疗
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CA2808091C (en) 2010-08-11 2019-05-21 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US8802114B2 (en) 2011-01-07 2014-08-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP6312592B2 (ja) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
EP2832361A1 (en) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Aqueous sustained release compositions of LHRH analogs
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN105749245A (zh) * 2016-03-02 2016-07-13 张光泉 抗癌药醋酸地加瑞克注射液及其制备方法
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4248864A (en) * 1979-08-30 1981-02-03 American Home Products Corporation Reproduction control
DE3371281D1 (en) * 1982-12-10 1987-06-11 Syntex Inc Lhrh preparations for intranasal administration
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4661472A (en) * 1985-05-09 1987-04-28 The Salk Institute For Biological Studies GnRH antagonists IX
US4851385A (en) * 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
DD273980B5 (de) * 1988-07-12 1994-04-14 Berlin Chemie Ag Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection
SU1680198A1 (ru) * 1990-08-09 1991-09-30 Центральный институт усовершенствования врачей Способ лечени реактивных артритов
DE4117507A1 (de) * 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
DK0686045T3 (da) * 1993-02-23 2001-03-05 Genentech Inc Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1101701C (zh) * 1993-06-29 2003-02-19 凡林有限公司 由鼻给药的去氨加压素组合物及其制备方法和用途
US5413990A (en) * 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
PL189137B1 (pl) * 1996-02-02 2005-06-30 Alza Corp Implantowane urządzenie do dostarczania substancji aktywnej

Also Published As

Publication number Publication date
JP2008291037A (ja) 2008-12-04
JP2001504442A (ja) 2001-04-03
CO4890855A1 (es) 2000-02-28
ES2213828T3 (es) 2004-09-01
TW586932B (en) 2004-05-11
EP0909177B1 (en) 2004-02-11
CN1256146C (zh) 2006-05-17
BR9710131A (pt) 1999-08-10
RO120611B1 (ro) 2006-05-30
HUP0000589A2 (hu) 2000-09-28
CZ433998A3 (cs) 1999-04-14
MY125556A (en) 2006-08-30
DE69727572D1 (de) 2004-03-18
ID19305A (id) 1998-07-02
CN1224357A (zh) 1999-07-28
WO1998000157A1 (en) 1998-01-08
DE69727572T2 (de) 2004-12-16
SK179898A3 (en) 1999-06-11
NO986208D0 (no) 1998-12-30
IL127770A0 (en) 1999-10-28
US6068850A (en) 2000-05-30
HK1020677A1 (en) 2000-05-19
US5916582A (en) 1999-06-29
PL330903A1 (en) 1999-06-07
HU225691B1 (en) 2007-06-28
PL189403B1 (pl) 2005-08-31
ATE259241T1 (de) 2004-02-15
NO323296B1 (no) 2007-03-05
CA2259505A1 (en) 1998-01-08
AU3574897A (en) 1998-01-21
SK284283B6 (sk) 2005-01-03
ZA975943B (en) 1998-04-16
RU2201248C2 (ru) 2003-03-27
NZ333579A (en) 2000-06-23
IL127770A (en) 2006-10-31
CZ298464B6 (cs) 2007-10-10
NO986208L (no) 1998-12-30
HUP0000589A3 (en) 2001-04-28
EP0909177A1 (en) 1999-04-21

Similar Documents

Publication Publication Date Title
AR007715A1 (es) Formulacion acuosa estable de un peptido, un metodo para preparar la misma y su uso para tratamiento
FI960012L (fi) Vedellinen, monifaasinen, stabiili valmisformulaatti kasvinsuojelussa käytettäviä vaikuttavia aineita varten ja menetelmiä sen valmistamiseksi
WO2002043750A8 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
UA42061C2 (uk) Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса
DE69434418D1 (de) Orale Dareichungsform
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
HU9600574D0 (en) Multiple unit pharmaceutical preparation containing proton pump inhibitor
EP0458894A4 (en) LIPID EXCIPIENT FOR NASAL ADMINISTRATION AND OTHER LOCAL APPLICATIONS.
PT974350E (pt) Preparacao contendo tranilast para aplicacao externa e metedo para a sua producao
PL268927A1 (en) Method of obtaining novel derivatives of benzimidazole
DK0582239T3 (da) Farmaceutisk og/eller kosmetisk formulering
DK1146896T3 (da) Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger
ATE311227T1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
PL311637A1 (en) Poured over preparations containing a polymer as well as glycerides and glycols
GB2328872B (en) Method for preparing pharmaceutical formulations
ES2111102T3 (es) Formulaciones cosmeticas y dermatologicas con un contenido activo en acido cis-urocaninico.
FI972004L (fi) Implantoitava laite vaikuttavien aineiden antamiseen kasveille
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
IT1204777B (it) Composizione per la preparazione estemporanea di formulazioni per applicazioni topiche per uso farmaceutico e cosmetico
NZ219300A (en) Veterinary composition for release of actives into the rumen
ATE258446T1 (de) Benzophenanthridinalkaloid-enthaltende pestizide
DK0873134T3 (da) Langvarig frigørelsesformulering omfattende bovin væksthormon frigørende faktor
DE59205998D1 (de) Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung
WO1998029131A3 (en) Aqueous glycerol formulations of somatotropin

Legal Events

Date Code Title Description
FB Suspension of granting procedure